Chronic Urticaria Clinical Trial
Official title:
Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test (UCT)
Chronic urticaria symptoms commonly fluctuate from day by day. Consequently the clinical presentation of a patient in each visit is not representative of the current disease status. Dermatologists are trying to integrate an evaluation process of each treatment visit regarding both clinical condition and life quality concern. The Urticaria Control Test is the key for a better treatment outcome in a routine management. To translate this questionnaire into Thai is essential in our subject of interest for offering local patients a higher well-being standard. The Thai-version test will encourage enhanced as well as impactful therapeutic options for Thai chronic urticaria patients.
1. Independently adaption of the UCT questionnaire into Thai version by using
forward-backward translation by two bilingual translators. The original German version
is translated into Thai by two Thai native speakers, then the study team reviews the
Thai-version UCT questionnaire for items comprehensibility and integrates the first
consensus version which re-translated into German by German native speaker afterwards.
The comparison between the backward German version UCT questionnaire and the original
UCT is carried out to find out any misconception and mistranslation in the intermediary
forward version of questionnaire. The second version will be tested on 15 chronic
urticaria patients to detect any misunderstanding points. Finally, this Thai-version of
UCT questionnaire will be used to investigate the validity, reliability,
interpretability and minimal clinical important difference.
2. To investigate the validity, reliability and interpretability of Thai-version of
Urticaria Control Test, the severity of urticaria symptoms will be assessed by
investigators and patients using UAS28, Patient's global assessment of disease severity
(PatGA-LS), Physician's global assessment of disease control (PhyGA-LS), the UCT and
DLQI questionnaire
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02435238 -
AWARE - Chronic Urticaria
|
N/A | |
Not yet recruiting |
NCT05513079 -
Positive Psychotherapy-Based Counseling (PPT)
|
N/A | |
Terminated |
NCT02047136 -
Dietary Treatment for Chronic Urticaria
|
N/A | |
Completed |
NCT01803763 -
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
|
Phase 2/Phase 3 | |
Terminated |
NCT01170949 -
Efficacy and Safety of Miltefosine in Antihistamine Resistant Chronic Urticaria
|
Phase 2 | |
Completed |
NCT00598611 -
Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)
|
Phase 3 | |
Completed |
NCT01610128 -
Development of an Urticaria Control Test
|
N/A | |
Completed |
NCT02285023 -
The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire
|
||
Completed |
NCT01715740 -
Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria
|
Phase 3 | |
Completed |
NCT01960283 -
Methotrexate in the Treatment of Chronic Idiopathic Urticaria
|
Phase 3 | |
Completed |
NCT00481676 -
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
|
Phase 2 | |
Completed |
NCT01713725 -
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
|
Phase 2 | |
Completed |
NCT01250652 -
Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High Doses
|
Phase 4 | |
Completed |
NCT01111136 -
Stress Intervention for Chronic Urticaria
|
N/A | |
Recruiting |
NCT01425593 -
T Cell Function in Chronic Idiopathic Urticaria
|
N/A | |
Completed |
NCT00628108 -
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
|
Phase 3 | |
Completed |
NCT00619801 -
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin
|
Phase 3 | |
Completed |
NCT00737451 -
Association of Thyroid Autoimmunity and Chronic Urticaria
|
N/A | |
Completed |
NCT01284426 -
Natural History of Chronic Urticaria
|
N/A | |
Withdrawn |
NCT01073852 -
Hydroxychloroquine Efficacy in Chronic Urticaria
|
N/A |